Drug Details
General Information of the Drug (ID: DR2915) | ||||
---|---|---|---|---|
Name |
Abivertinib
|
|||
Synonyms |
Avitinib; 1557267-42-1; N-(3-((2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; Avitinib free base; SCHEMBL15453394; KS-00000TON; EX-A783; MolPort-042-663-560; Avitinib(AC0010/AC0010MA); ZINC142081723; AKOS030632728; CS-W008904; N-(3-{2-[3-Fluoro-4-(4-methyl-piperazin-1-yl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy}-phenyl)-acrylamide; DS-19269; AK543905; 2-Propenamide, N-[3-[[2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Lung cancer [ICD-11: 2C25] | Phase 1 | [1] | |
Structure |
![]() |
Click to Download Mol2D MOL |
||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C26H26FN7O2
|
|||
PubChem CID | ||||
Canonical SMILES |
CN1CCN(CC1)C2=C(C=C(C=C2)NC3=NC4=C(C=CN4)C(=N3)OC5=CC=CC(=C5)NC(=O)C=C)F
|
|||
InChI |
1S/C26H26FN7O2/c1-3-23(35)29-17-5-4-6-19(15-17)36-25-20-9-10-28-24(20)31-26(32-25)30-18-7-8-22(21(27)16-18)34-13-11-33(2)12-14-34/h3-10,15-16H,1,11-14H2,2H3,(H,29,35)(H2,28,30,31,32)
|
|||
InChIKey |
UOFYSRZSLXWIQB-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 1557267-42-1
|
|||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Apigenin | Psilotum nudum | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | GSK-3B | Molecule Info |
Pathway MAP
|
|
In-vitro Model | U-2932 | CVCL_1896 | B-cell lymphoma | Homo sapiens | ||
OCI-Ly10 | CVCL_8795 | B-cell lymphoma | Homo sapiens | |||
Experimental
Result(s) |
Apigenin can synergize with Abivertinib in treating DLBCL visa synergistically inducing apoptosis and inhibiting the p-GS3K-beta and its downstream targets. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Epidermal growth factor receptor (EGFR) | Molecule Info | [1] | |
KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
2 | ErbB signaling pathway | |||
3 | Ras signaling pathway | |||
4 | Rap1 signaling pathway | |||
5 | Calcium signaling pathway | |||
6 | Cytokine-cytokine receptor interaction | |||
7 | HIF-1 signaling pathway | |||
8 | FoxO signaling pathway | |||
9 | Endocytosis | |||
10 | PI3K-Akt signaling pathway | |||
11 | Dorso-ventral axis formation | |||
12 | Focal adhesion | |||
13 | Adherens junction | |||
14 | Gap junction | |||
15 | Regulation of actin cytoskeleton | |||
16 | GnRH signaling pathway | |||
17 | Estrogen signaling pathway | |||
18 | Oxytocin signaling pathway | |||
19 | Epithelial cell signaling in Helicobacter pylori infection | |||
20 | Hepatitis C | |||
21 | Pathways in cancer | |||
22 | Proteoglycans in cancer | |||
23 | MicroRNAs in cancer | |||
24 | Pancreatic cancer | |||
25 | Endometrial cancer | |||
26 | Glioma | |||
27 | Prostate cancer | |||
28 | Melanoma | |||
29 | Bladder cancer | |||
30 | Non-small cell lung cancer | |||
31 | Central carbon metabolism in cancer | |||
32 | Choline metabolism in cancer | |||
NetPath Pathway | IL4 Signaling Pathway | Click to Show/Hide | ||
2 | EGFR1 Signaling Pathway | |||
Panther Pathway | Cadherin signaling pathway | Click to Show/Hide | ||
2 | EGF receptor signaling pathway | |||
Pathway Interaction Database | LPA receptor mediated events | Click to Show/Hide | ||
2 | Signaling events mediated by PTP1B | |||
3 | Arf6 signaling events | |||
4 | Signaling events mediated by TCPTP | |||
5 | Thromboxane A2 receptor signaling | |||
6 | SHP2 signaling | |||
7 | Regulation of Telomerase | |||
8 | EGF receptor (ErbB1) signaling pathway | |||
9 | EGFR-dependent Endothelin signaling events | |||
10 | Posttranslational regulation of adherens junction stability and dissassembly | |||
11 | Direct p53 effectors | |||
12 | ErbB1 downstream signaling | |||
13 | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||
14 | E-cadherin signaling in keratinocytes | |||
15 | ErbB receptor signaling network | |||
16 | Internalization of ErbB1 | |||
17 | Stabilization and expansion of the E-cadherin adherens junction | |||
18 | a6b1 and a6b4 Integrin signaling | |||
19 | Syndecan-3-mediated signaling events | |||
Reactome | Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | Click to Show/Hide | ||
2 | SHC1 events in ERBB2 signaling | |||
3 | PLCG1 events in ERBB2 signaling | |||
4 | PIP3 activates AKT signaling | |||
5 | GRB2 events in EGFR signaling | |||
6 | GAB1 signalosome | |||
7 | SHC1 events in EGFR signaling | |||
8 | EGFR downregulation | |||
9 | GRB2 events in ERBB2 signaling | |||
10 | PI3K events in ERBB2 signaling | |||
11 | EGFR Transactivation by Gastrin | |||
12 | Constitutive Signaling by Aberrant PI3K in Cancer | |||
13 | Constitutive Signaling by EGFRvIII | |||
14 | RAF/MAP kinase cascade | |||
WikiPathways | ErbB Signaling Pathway | Click to Show/Hide | ||
2 | Regulation of Actin Cytoskeleton | |||
3 | EGF/EGFR Signaling Pathway | |||
4 | MAPK Signaling Pathway | |||
5 | Focal Adhesion | |||
6 | Aryl Hydrocarbon Receptor Pathway | |||
7 | Extracellular vesicle-mediated signaling in recipient cells | |||
8 | TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer | |||
9 | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | |||
10 | Bladder Cancer | |||
11 | Hair Follicle Development: Induction (Part 1 of 3) | |||
12 | Signaling by ERBB4 | |||
13 | Signaling by ERBB2 | |||
14 | Gastrin-CREB signalling pathway via PKC and MAPK | |||
15 | PIP3 activates AKT signaling | |||
16 | Nanoparticle-mediated activation of receptor signaling | |||
17 | Aryl Hydrocarbon Receptor | |||
18 | Spinal Cord Injury | |||
19 | Integrated Pancreatic Cancer Pathway | |||
20 | Gastric cancer network 2 | |||
21 | AGE/RAGE pathway | |||
22 | Signaling Pathways in Glioblastoma | |||
23 | Arylhydrocarbon receptor (AhR) signaling pathway | |||
24 | miR-targeted genes in muscle cell - TarBase | |||
25 | miR-targeted genes in lymphocytes - TarBase | |||
26 | miR-targeted genes in epithelium - TarBase | |||
27 | Integrated Breast Cancer Pathway | |||
28 | Signaling by EGFR | |||
29 | L1CAM interactions |
